• New Launches

Eisai’s Fycompa for Adjunctive Treatment of Partial Onset Seizures Launched in China

New Delhi, January 07, 2019: Eisai Co., Ltd. has launched the in-house discovered and developed antiepileptic drug (AED) Fycompa, (generic…

• Approval

Eisai’s Anticancer Agent Halaven Approved for Treatment of Locally Advanced or Metastatic Breast Cancer in China

Tokyo, July 17, 2019: Eisai has received a New Drug Approval for its in-house developed anticancer agent Halaven (eribulin mesylate)…

• Drug Discovery & Development

Eisai Center for Genetics Guided Dementia Discovery Commences Full-Scale Operation Toward Innovative Dementia Treatments With New Drug Discovery Approach in Cambridge, Massachusetts

A Focused Drug Discovery Approach That Integrates Human Genetics/ Data Science/ Precision Chemistry Tokyo, July 10, 2019: Eisai Co., Ltd.…

• Latest

“Science Based Targets (SBT) Initiative” Approves Eisai’s Greenhouse Gas Reduction Targets

Tokyo, May 21, 2019: Eisai Co., Ltd. announced today that Eisai has received approval from "Science Based Targets (SBT) Initiative"…

Eisai’s Supplementary New Drug Application Submitted In Japan for Fycompa

As Monotherapy for Partial-Onset Seizures, Pediatric Indication for Partial-Onset Seizures, as Well as New Formulation Tokyo, February 03, 2019: Eisai Co., Ltd.…

Eisai’s LENVIMA (LENVATINIB) Capsules Approved for First-Line Treatment of Unresectable Hepatocellular Carcinoma (HCC) in South Korea

Tokyo, Septembe 02, 2018: Eisai Co., Ltd. announced that its South Korea subsidiary Eisai Korea Inc. received approval for the…